Background
As more biologics are approved, there is increasing interest in comparative eff ectiveness research (CER). Health insurance claims databases contain information about outpatient visits, hospital discharges, procedures, and outpatient pharmacy dispensing but seldom contain clinical outcomes. In a previous issue of Arthritis Research & Th erapy, we presented an algorithm that assessed the clinical eff ectiveness of rheumatoid arthritis (RA) biologics which used Veterans Aff airs (VA) claims data and which was validated against the DAS28-ESR (Disease Activity Score 28 using erythrocyte sedimen tation rate) [1] . Th e algorithm had a sensitivity of 72% (95% confi dence interval (CI) = 67% to 77%) and a specifi city of 91% (95% CI = 89% to 93%). In an editorial in the same issue, Kim and Solomon [2] commented the following: 'a claims-based eff ectiveness algorithm with acceptable performance characteristics across diff erent data settings will be a powerful and desired tool for CER of RA. Such an algorithm will enable large-scale, population-based studies comparing the eff ectiveness of diff erent DMARD [disease-modifying antirheumatic drug] regimens. Such studies will facilitate head-to-head comparisons, supplement ing typical randomized controlled trials and prospective registries that usually include disease activity. Whether the algorithm will have a similar performance in other claims databases therefore needs to be further examined' . We performed an independent analysis to evaluate the algorithm's positive predictive value (PPV) in a commercial claims data source compared with a clinical gold standard.
Methods
Data came from a previous comparative eff ectiveness study linking outpatient medical records from multiple US institutions and physician practices to commercial claims data from OptumInsight (Eden Prairie, MN, USA) [3] that evaluated the eff ectiveness of etanercept (ETN), adalimumab (ADA), and infl iximab (INF) in biologic naïve adult RA patients persistent on their initial biologic for at least 1 year from 2006 to 2008. Two teams of two rheumatologists reviewed each medical record and categorized clinical change around 1 year as 'much better' , 'better' , 'no change' , 'worse' , or 'much worse' . For this study, the biologic was considered eff ective if the patient was rated as 'better' or 'much better' . Sensitivity, specifi city, and negative predictive value could not be determined, because patients switching biologic agents were excluded from the original study. Th e PPV compared the classifi cation from the algorithm to the rheumatologist rating. Diff erent compliance thresholds with the biologic medications used by the algorithm were evaluated as sensitivity analyses.
Result
Th e majority (76%) of the 429 patients in the study were female, and the mean age was 51 years. Th e PPVs were 86.6% in the primary analysis and 86.5% in sensitivity analyses, similar to that of the original algorithm using VA data. PPV did not diff er signifi cantly by biologic (P >0.2): INF (PPV = 95%), ETN (PPV = 86%), and ADA (PPV = 85%).
Conclusions
Th is previously published administrative claims-based eff ectiveness algorithm had a high PPV across commercial claims data and VA data. Th is algorithm may be useful in evaluating the eff ectiveness of biologic agents by administrative claims data in future studies. 
